A damaging trial failure in December wiped 70% off the share price of BioAge Labs, a US biopharma developing therapeutic ...

Metsera is aiming to put its weight loss drug MET-097i, which boasts of a longer half-life, through Phase III trials.

Denmark’s Novo Nordisk saw its shares rise as much as 13% to 659.20 kroner this morning, after it announced top-line results ...

Eli Lilly (NYSE: LLY) sells many products across treatment areas, from immunology to neuroscience. The company sells ...

Zepbound® (tirzepatide) provided a 47% greater relative ... Nov. 20, 2024 (GLOBE NEWSWIRE) -- Verge Genomics, a clinical-stage biotechnology company pioneering the use of artificial intelligence ...

The proposal, unveiled at the government's International Investment Summit today is headlined by the creation of a UK biotech hub ... evidence study involving tirzepatide, the dual GIP/GLP ...

The biotech believes that azelaprag can amplify the weight loss achieved with tirzepatide and other obesity drugs, and also improve the body composition of treated patients by preserving muscle ...

The ClearBridge Large Cap Growth ESG Strategy underperformed its Russell 1000 Growth Index benchmark in the fourth quarter.

Obesity programs: <li /> Phase 2 BMT-801 clinical study with MC4R agonist bremelanotide plus GLP-1/GIP dual agonist tirzepatide ...

Hydreight Technologies Inc. ("Hydreight"or the "Company"), a fast-growing mobile clinical network and medical platform which enables flexible at-home medical services across 50 states in the United ...